Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...
Iowans are more likely to develop lung cancer than the average American. Demographics and even geology play a role, but ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...
Australian researchers say they have identified a new, highly targeted way to attack myelofibrosis, a rare and serious blood ...
In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...
Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback